Bullous pemphigoid in 65 years old female: a case report

Introduction: Bullous pemphigoid is an autoimmune disorder. The incidence of bullous pemphigoid has increased over time, current understanding regarding treatment and complication is an important issue considering the disease often occur in elderly resulting in high rates of morbidity to the patients. Aim of current case report is to describe the clinical relevance regarding symptom and treatment of bullous pemphigoid.Case presentation: A 65 years old female patient, came with chief complaints of bullae in abdominal region with itching and burning sensation in the ruptured bullae. Over time bullae spread in lower and upper extremity. Patient was admitted for four days with therapy intravenous steroids, oral antihistamine, and potent topical steroids. Patient was discharged from hospital in well condition.Conclusion: Bullous pemphigoid is an inflammatory autoimmune skin disease and usually result in good prognosis with adequate management.Keywords: autoimmune, bullous, pemphigoid, skin, disease.

Download Full-text

A Case Report on Idiopathic Severe Bullous Pemphigoid

Journal of Drug Delivery and Therapeutics ◽

10.22270/jddt.v10i4-s.4311 ◽

2020 ◽

Vol 10 (4-s) ◽

pp. 223-225

Author(s):

Fizza Khan Mohammadi ◽

Sultana Zoha ◽

Mohammed Baleeqhuddin ◽

Salman Mir Ali ◽

Abdullah Md. Faizan

Keyword(s):

Bullous Pemphigoid ◽

Autoimmune Disorder ◽

The Body ◽

Topical Steroids ◽

Adequate Treatment ◽

Systemic Corticosteroids ◽

Bullous Lesion ◽

Clinical Presentations ◽

Chief Complaints ◽

Laboratory Investigations

Bullous Pemphigoid (BP) is an autoimmune disorder which exploits the immune system and affecting sub-epidermal region of skin causing mild itching to infection and blistering of sub-epidermal region. Clinical presentations are pruritis, urticarial, papular lesions. These later evolve to bullae in weeks to months and are typically present in the axillae, on the flexor surface of the forearms, medial thighs, trunk, and abdomen. The treatment for bullous pemphigoid is systemic corticosteroids, topical steroids in combination with nicotinamide plus tetracycline, minocycline or doxycycline have shown success in multiple cases. Immunosuppressive therapy is used when steroids do not control the disease or if patients have contraindications for systemic corticosteroid treatments. Patient was brought to emergency department with chief complaints itching, redness, bullous lesion all over the body for 2 months.Oral complaints including solitary erosion seen on right side of buccal mucosa, pharyngeal erythema. Laboratory investigations were carried out. Patient was diagnosed based on physical examination. Patient was provided with adequate treatment and counseling. Keywords: Bullous Pemphigoid, corticosteroid, Autoimmune disorder, sub-epidermal region.

Download Full-text

Bullous Pemphigoid in an Infant: A Case Report

Prehospital and Disaster Medicine ◽

10.1017/s1049023x18000456 ◽

2018 ◽

Vol 33 (4) ◽

pp. 448-450 ◽

Cited By ~ 1

Author(s):

Oscar Thabouillot ◽

Julien Le Coz ◽

Nicolas-Charles Roche

Keyword(s):

Emergency Department ◽

Differential Diagnosis ◽

Case Report ◽

General Practitioner ◽

Prior Knowledge ◽

Bullous Pemphigoid ◽

Skin Disease ◽

Topical Steroids ◽

Johnson Syndrome ◽

Steven Johnson Syndrome

AbstractA seven-month-old girl was referred to the emergency department (ED) after a general practitioner suspected Steven-Johnson syndrome. Actually, the diagnosis of bullous pemphigoid (BP) was made based on biopsies; BP is a rare, autoimmune skin disease involving the presence of blisters known as bullae. The child was efficiently treated with topical steroids. This case shows the importance of the ED physician’s prior knowledge of BP so that a differential diagnosis with other autoimmune diseases (dermatosis, pemphigus) can be made.Thabouillot O, Le Coz J, Roche NC. Bullous pemphigoid in an infant: a case report. Prehosp Disaster Med. 2018;33(4):448–450.

Download Full-text

Extensive cutaneous iatrogenic Kaposi’s sarcoma after bullous pemphigoid treatment with oral methylprednisolone: a rare Chinese case report

Journal of International Medical Research ◽

10.1177/0300060520982829 ◽

2021 ◽

Vol 49 (1) ◽

pp. 030006052098282

Author(s):

Sheng-An Chen ◽

Lan-Ting Wang ◽

Zi-Hua Chen ◽

Fan-Ping Yang ◽

Qin-Yuan Zhu ◽

...

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Kaposi's Sarcoma ◽

Human Herpesvirus ◽

Kaposi’S Sarcoma ◽

Lower Limbs ◽

Ki 67 ◽

Current Case ◽

Barr Virus ◽

Epstein Barr

Bullous pemphigoid (BP) is an autoimmune disease that requires immunosuppressive therapy. Systemic corticosteroids are considered the standard treatment for moderate-to-severe BP. Kaposi’s sarcoma (KS) is a rare multifocal endothelial tumour that affects the skin, mucosa and viscera. As an angioproliferative disease of obscure aetiopathogenesis and histogenesis, KS is associated with human herpesvirus 8 (HHV-8). This current case report describes a rare occurrence of extensive cutaneous KS in a 60-year-old Chinese male patient after oral methylprednisolone treatment for BP with an emphasis on its pathological characterization. A total of more than 40 nodules were found on his trunk and lower limbs covering more than 20% of his body surface area. Immunohistochemical staining of biopsy samples from the lesion showed the patient was positive for HHV-8, CD31, CD34, XIIIa, ERG and Ki-67. The Epstein–Barr virus test showed the patient tested negative for immunoglobulin (Ig)A and IgM, but was positive for IgG. Immunosuppression associated with the treatment for BP may activate a latent HHV-8 infection and induce the development of KS.

Download Full-text

Bullous Pemphigoid an Autoimmune Skin Disease: A Case Report

International Journal of Pharmaceutical Sciences Review and Research ◽

10.47583/ijpsrr.2020.v65i01.024 ◽

2020 ◽

Vol 65 (1) ◽

pp. 161-163

Author(s):

Maheshwari V ◽

Tasneem Abdul Gafoor ◽

Ajeena Anto ◽

Syam Prakash KR ◽

Shahina KP ◽

...

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Skin Disease

Download Full-text

BULLOUS PEMPHIGOID A RARE AUTOIMMUNE DISEASE: A CASE REPORT

International Journal of Medicine and Medical Research ◽

10.11603/ijmmr.2413-6077.2018.2.9248 ◽

2019 ◽

Vol 4 (2) ◽

pp. 20-23

Author(s):

S. M. Biradar ◽

S. Dhanavidya ◽

P. Kavya ◽

T. Keerthi ◽

N. Sunanda ◽

...

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Male Patient ◽

Skin Disease ◽

The Elderly ◽

Skin Lesions ◽

Treatment Modalities ◽

Susceptibility To Infection ◽

Electrolyte Disturbances ◽

Upper And Lower Extremities

Background. Bullous pemphigoid (BP) is a rare autoimmune blistering skin disease in the elderly and it is manifested by cutaneous blisters on the skin lesions. The objective was to emphasize the rare case of BP. Methods. A case report of BP in a 58-year-old male patient admitted to a dermatology ward is presented. Results. A 58-year-old male patient with complaints of fluid-filled skin lesions, was examined initially over the trunk, gradually progressed involving B/L upper and lower extremities. Even though the patient was treated with the recommended therapy of corticosteroid (Dexamethasone) along with adjuvant drugs, new skin lesions continued to develop, and the patient’s condition worsened. The Prednisolone was started in place of Dexamethasone on the fifth day of treatment at its higher dose (50mg/day), the Prednisolone proved its efficacy to combat the extensive condition of BP. Conclusions. Bullous pemphigoid is a distressing blistering skin disease. Untreated disease is often fatal because of the susceptibility to infection and fluid-electrolyte disturbances. The mortality of patients with bullous pemphigoid has been significantly reduced with the advent of new therapies and treatment modalities. The treatment with systemic and topical corticosteroids forms the mainstay of treatment along with other adjuvant drugs. In the present case study, the use of Prednisolone has proven its efficacy in the extensive disease state of BP and improved the patient’s quality of life.

Download Full-text

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Frontiers in Immunology ◽

10.3389/fimmu.2020.611549 ◽

2021 ◽

Vol 11 ◽

Author(s):

S. Morteza Seyed Jafari ◽

Laurence Feldmeyer ◽

Simon Bossart ◽

Dagmar Simon ◽

Christoph Schlapbach ◽

...

Keyword(s):

Monoclonal Antibody ◽

Case Report ◽

Combination Therapy ◽

Beneficial Effect ◽

Bullous Pemphigoid ◽

Skin Disease ◽

Case Series ◽

Complete Response ◽

Preliminary Results ◽

Alpha Antagonist

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Download Full-text

Bullous pemphigoid: Case report and review of literature

Hellenic Archives of Oral and Maxillofacial Surgery ◽

10.54936/haoms222125128 ◽

2021 ◽

pp. 125-128

Author(s):

Shunmugavelu KARTHIK ◽

Shanmugam ARASU ◽

Srikanthan SRIRAM ◽

Evangeline Cynthia DHINAKARAN ◽

Yalamanchi ANUSHA ◽

...

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Chief Complaint ◽

Topical Steroids ◽

Oral Lesions ◽

Incisional Biopsy ◽

Review Of Literature ◽

The Past ◽

Bullous Disease ◽

Autoimmune Bullous Disease

Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by subepithelial blistering mostly affecting elderly but may be seen in all ages. A 52-year-old female patient came with a chief complaint of itching, redness and ulcer in the hands and oral cavity for the past 2 weeks. The examination revealed ulcer- ated lesions in palate and buccal mucosa. Erythematous lesions were also seen in upper limb. Incisional biopsy was done and histological examination revealed bullous pemphigoid. The patient was immediately started with systemic and topical steroids and was continued for 3 weeks. The extra-oral lesions were healed and intraoral ulcerations subsided after 3 weeks.

Download Full-text

A CASE REPORT ON CHARMADAL THROUGH PANCHAKARMA W.S.R. TO ECZEMA

International Journal of Ayurveda and Pharma Research ◽

10.47070/ijapr.v8i7.1504 ◽

2020 ◽

pp. 37-41

Author(s):

Parwati ◽

Kavita ◽

Swarnakant jena ◽

Santosh Kumar Bhatted ◽

Prasanth Dharmarajan

Keyword(s):

Atopic Dermatitis ◽

Case Report ◽

Topical Steroids ◽

Text Line ◽

Body Parts ◽

Upper Arm ◽

Satisfactory Treatment ◽

Chief Complaints

Charmadal is a type of Kshudrakushta characterized with symptoms such as redness, itching, pustules, pain and cracks in the skin and tenderness. Most of the symptoms of Eczema can be correlated with Charmadal as mentioned in Ayurvedic classics. A diagnosed case of Eczema came with chief complaints of red patches on skin associated with severe itching, burning and dryness over different body parts (on face, neck, upper arm) since 4 years with complaint of oozing of blood from the patches after itching. No satisfactory treatment is present except topical steroids, but in Ayurveda text line of treatment for Charmadal is present i.e., Virechana Karma”. Before giving Virechana treatment SCORAD (Scoring atopic dermatitis) was 26.55% and after follow up SCORAD 86.05%. Before Virechana treatment DLQI was 25% (extremely large effect on patient’s life) and after follow up DLQI was 4% (small effect on patient life). The results of the study showed that when Virechana Karma was performed, it increased the efficacy of oral Ayurveda medicines in the patient of Charmadal. Virechana improved the condition of patient to very much extent.

Download Full-text